GlobeNewswire·Nov 5, 2026, 4:34 PM ET

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update

Nkarta, Inc. will present initial clinical data for its NKX019 therapy in idiopathic inflammatory myopathy & systemic sclerosis at ACR Convergence 2026 in Orlando, featuring two oral presentations & one poster.
The company holds a cash balance of $216.0 million as of September 30, 2026, which is expected to fund operations into 2029.
Enrollment continues in the multi-center Ntrust-1 & Ntrust-2 trials, with outpatient dosing now active at community-based sites to treat 4 billion cells per dose across three doses.
Third quarter 2026 research & development expenses totaled $29.5 million, while general & administrative expenses were $6.3 million.
The company reported a net loss of $33.3 million ($0.45 per share) for the third quarter of 2026, which included $2.8 million in non-cash charges.
NKX019 is an allogeneic, off-the-shelf CAR-NK cell therapy targeting CD19 to eliminate pathogenic B cells in autoimmune diseases via a three-dose cycle following lymphodepletion.
The Ntrust trials are enrolling up to 12 patients per dose level across leading indications including myositis, systemic sclerosis, rheumatoid arthritis, lupus nephritis, & ANCA-associated vasculitis.